Efgartigimod alfa is under clinical development by Argenx and currently in Phase III for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic ... nephropathy), lupus nephritis and Sjogren's ...
and tinhibiting complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome (aHUS). Epysqli, manufactured by Samsung Bioepis Co. Ltd., obtained initial approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback